Research programme: orphan disease therapeutics - Aevi Genomic Medicine/The Childrens Hospital of Philadelphia

Alternative Names: AEVI-005; MDGN-204; MDGN-206

Latest Information Update: 13 Mar 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Medgenics; The Childrens Hospital of Philadelphia
Developer Aevi Genomic Medicine; Kyowa Hakko Kirin; The Childrens Hospital of Philadelphia
Class Gene therapies; Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Metabolic disorders
Research Autoimmune disorders

Most Recent Events

07 Mar 2018 Aevi Genomic Medicine and Kyowa Hakko Kirin agree to co-develop monoclonal antibody for ultra-orphan paediatric indication
07 Mar 2018 Early research in Autoimmune disorders in Japan and USA (Parenteral)
15 Dec 2016 Medgenics is now called Aevi Genomic Medicine

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.